Apollo Endosurgery Stock Forecast, Price & News

+0.01 (+0.12 %)
(As of 06/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume149,820 shs
Average Volume550,059 shs
Market Capitalization$234.94 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive APEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Apollo Endosurgery and its competitors with MarketBeat's FREE daily newsletter.

Apollo Endosurgery logo

About Apollo Endosurgery

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, and delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands; and Orbera Coach, a digital and remotely delivered aftercare program. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Brazil, Australia, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.53 out of 5 stars

Medical Sector

539th out of 2,105 stocks

Surgical & Medical Instruments Industry

45th out of 174 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions

Is Apollo Endosurgery a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Apollo Endosurgery stock.
View analyst ratings for Apollo Endosurgery
or view top-rated stocks.

What stocks does MarketBeat like better than Apollo Endosurgery?

Wall Street analysts have given Apollo Endosurgery a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Apollo Endosurgery wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Apollo Endosurgery?

Apollo Endosurgery saw a increase in short interest in the month of May. As of May 14th, there was short interest totaling 206,700 shares, an increase of 116.2% from the April 29th total of 95,600 shares. Based on an average daily volume of 846,200 shares, the days-to-cover ratio is currently 0.2 days. Approximately 1.4% of the company's shares are short sold.
View Apollo Endosurgery's Short Interest

When is Apollo Endosurgery's next earnings date?

Apollo Endosurgery is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Apollo Endosurgery

How were Apollo Endosurgery's earnings last quarter?

Apollo Endosurgery, Inc. (NASDAQ:APEN) released its earnings results on Monday, May, 3rd. The biotechnology company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.05. The biotechnology company had revenue of $13.86 million for the quarter, compared to the consensus estimate of $11.78 million. Apollo Endosurgery had a negative net margin of 37.52% and a negative trailing twelve-month return on equity of 730.71%.
View Apollo Endosurgery's earnings history

How has Apollo Endosurgery's stock price been impacted by Coronavirus?

Apollo Endosurgery's stock was trading at $2.0650 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APEN stock has increased by 320.8% and is now trading at $8.69.
View which stocks have been most impacted by COVID-19

What price target have analysts set for APEN?

2 brokers have issued 1-year target prices for Apollo Endosurgery's stock. Their forecasts range from $11.00 to $12.00. On average, they anticipate Apollo Endosurgery's stock price to reach $11.50 in the next year. This suggests a possible upside of 32.3% from the stock's current price.
View analysts' price targets for Apollo Endosurgery
or view top-rated stocks among Wall Street analysts.

Who are Apollo Endosurgery's key executives?

Apollo Endosurgery's management team includes the following people:
  • Ms. Stefanie L. Cavanaugh, CFO, Treasurer & Sec. (Age 56, Pay $324.16k)
  • Mr. K. Todd Newton, Consultant (Age 58, Pay $482.64k)
  • Mr. Bret Schwartzhoff, VP, US Sales & Global Marketing (Age 48, Pay $345.98k)
  • Mr. Charles S. McKhann, CEO, Pres & Director (Age 52)
  • Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation Partner
  • Mr. Anthony Kalloo M.D., Co-Founder and Innovation Partner
  • Dr. Robert Hawes M.D., Co-Founder and Innovation Partner
  • Dr. Peter Benjamin Cotton M.D., Co-Founder and Innovation Partner
  • Dr. Christopher J. Gostout, Co-Founder & Chief Medical Officer (Age 70)
  • Mr. Sydney Chung M.D., Co-Founder and Innovation Partner

Who are some of Apollo Endosurgery's key competitors?

What other stocks do shareholders of Apollo Endosurgery own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), OPKO Health (OPK), Pfizer (PFE), Sunesis Pharmaceuticals (SNSS), Biocept (BIOC), Co-Diagnostics (CODX) and Second Sight Medical Products (EYES).

What is Apollo Endosurgery's stock symbol?

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

Who are Apollo Endosurgery's major shareholders?

Apollo Endosurgery's stock is owned by a number of institutional and retail investors. Top institutional shareholders include CPMG Inc (11.72%), Nantahala Capital Management LLC (8.43%), Gagnon Securities LLC (5.80%), Goldman Sachs Group Inc. (2.38%), Renaissance Technologies LLC (1.50%) and Manatuck Hill Partners LLC (0.93%). Company insiders that own Apollo Endosurgery stock include David Pacitti, John R Barr, Neil Gagnon and R Kent Mcgaughy Jr.
View institutional ownership trends for Apollo Endosurgery

Which institutional investors are selling Apollo Endosurgery stock?

APEN stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, and Nantahala Capital Management LLC.
View insider buying and selling activity for Apollo Endosurgery
or view top insider-selling stocks.

Which institutional investors are buying Apollo Endosurgery stock?

APEN stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Manatuck Hill Partners LLC, Gagnon Securities LLC, Parkman Healthcare Partners LLC, Millennium Management LLC, CPMG Inc, Neuberger Berman Group LLC, and Geode Capital Management LLC. Company insiders that have bought Apollo Endosurgery stock in the last two years include John R Barr, Neil Gagnon, and R Kent Mcgaughy Jr.
View insider buying and selling activity for Apollo Endosurgery
or or view top insider-buying stocks.

How do I buy shares of Apollo Endosurgery?

Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apollo Endosurgery's stock price today?

One share of APEN stock can currently be purchased for approximately $8.69.

How much money does Apollo Endosurgery make?

Apollo Endosurgery has a market capitalization of $234.94 million and generates $42.05 million in revenue each year. The biotechnology company earns $-22,610,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis.

How many employees does Apollo Endosurgery have?

Apollo Endosurgery employs 158 workers across the globe.

What is Apollo Endosurgery's official website?

The official website for Apollo Endosurgery is

Where are Apollo Endosurgery's headquarters?

Apollo Endosurgery is headquartered at 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746.

How can I contact Apollo Endosurgery?

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]

This page was last updated on 6/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.